Key Points
-
Interested in Geron Corporation? Here are five stocks we like better.
-
Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million, toward the midpoint to high end of its previously issued $220 million-$240 million guidance. The company reported record quarterly revenue of $57.5 million and three consecutive quarters of growth.
-
Commercial efforts are shifting toward community oncology practices, which account for about 80% of the lower-risk MDS market. Geron is adding 100 to 200 new RYTELO accounts per quarter, while 34% of business already comes from first- and second-line patients.
-
Geron plans to outline its European commercialization strategy before year-end and continues the 327-patient IMpactMF Phase 3 trial in relapsed or refractory myelofibrosis. The company ended the period with more than $300 million in…



